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INTRODUCTION
Although most advanced germ cell tumors (GCT) can be cured with initial cisplatinbased chemotherapy, 20-30% of patients demonstrate cisplatin resistance and require more intensive salvage chemotherapy programs or desperation surgery with 10-20% ultimately dying of this disease.(1) For such patients, novel therapies are needed.
While other tumor types have benefited greatly from the introduction of molecularly targeted therapies into oncologic practice, few novel targets and no new agents have been identified as effective against refractory GCT. Furthermore, mutations that confer chemotherapy resistance in somatic tumor types such as TP53 alterations have been rarely observed in GCT and, when present, are not universally associated with cisplatin resistance. (3) (4) (5) In 2009, Honecker and colleagues challenged this prevailing notion when they reported that 26% of 35 patients with cisplatin-resistant GCT had BRAF mutations as compared to 1% of 100 unselected GCT cases. (6) However, this finding has not been validated.
One study of adult GCT (7) found an incidence of BRAF mutations of only 5% (9% among nonseminomas and 0% among seminomas) and a report of pediatric and adolescent GCT (8) identified no BRAF mutations among 66 patients, including 18 diagnosed at age ≥13 and 15 with progressive disease after primary therapy. One additional series of 65 testicular GCT and 4 GCT cell lines also failed to identify any BRAF mutations. (9) Research.
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Author Manuscript Published OnlineFirst on May 8, 2014 ; DOI: 10.1158/1078-0432.CCR- In the current study, we attempted to validate the finding of frequent BRAF mutations among resistant GCT (with comparison to sensitive tumors) which would support routine BRAF testing in this population and potentially allow treatment with a BRAF inhibitor in mutation-positive patients. Mutations in KRAS, HRAS, NRAS, AKT1, PIK3CA, and FGFR3 were also interrogated to gain a better understanding of the spectrum of alterations in GCT, thereby providing a rationale to test novel agents targeting these signaling pathways in patients with resistant GCT.
PATIENTS AND METHODS

Patients
Patients were eligible to have their tumors analyzed if they had a diagnosis of GCT (of any primary site) confirmed by pathological review at Memorial Sloan Kettering Cancer Center, received cisplatin-based chemotherapy for advanced disease, and had adequate fresh frozen or paraffin-embedded tumor tissue available for DNA extraction.
In addition, information regarding patient outcome following cisplatin-based chemotherapy had to be available. Tumors could have been obtained from primary or metastatic sites and before or after chemotherapy. Written informed consent was obtained from all patients to allow use of their tumor for research purposes and the study was IRB-approved. follow-up before study entry (minimum of two years post-completion of chemotherapy).
For patients who underwent post-chemotherapy surgery, no residual GCT elements other than teratoma could be present within the pathologic specimen.
A tumor was classified as "cisplatin-resistant" when a patient developed progressive disease after first-line cisplatin-based chemotherapy (incomplete response or relapse) or if viable non-teratomatous GCT was identified at post-chemotherapy surgery. In order to select the most resistant cases, tumors from patients who died of progressive GCT were prioritized for inclusion.
Cell Lines
Nine GCT cell lines with varying degrees of sensitivity and resistance to cisplatin were subjected to the Sequenom assay, including eight derived from nonseminomas (NT2101, 27X1, NCC15, 169A, 218A, 228A, 2102EP, TERA-1) and one from a seminoma (TCAM2). 27X1, 169A, 218A, and 228A were generated in our laboratories whereas the remaining cell lines were obtained from commonly available sources.
Maintenance and relative cisplatin-resistance of the nonseminoma cell lines was previously described.(3)
DNA Extraction
Thirty-six samples were from fresh frozen tissue (FFT) and 39 from formalin-fixed paraffin-embedded (FFPE) blocks. All samples were reviewed by a board-certified GU pathologist (H.A.A. or V.E.R.) to confirm the diagnosis and estimate tumor content.
Research. Whenever possible, samples with ≥70% tumor content were utilized. In addition, in mixed nonseminomas containing secondary somatic malignant differentiation, an effort was made to select blocks containing predominantly viable GCT elements rather than the secondary somatic malignant histology. For the FFT samples, DNA was readily available, having been extracted for use in our previous studies.(10) DNA was extracted from paraffin samples using the Qiagen DNeasy kit (Valencia, CA). All concentrations were measured using the Nanodrop 2000 spectrophotometer.
Mutation Detection
Tumors were screened for hotspot alterations using a custom iPLEX assay (Sequenom, San Diego, CA). Briefly, multiplexed PCR and extension primers were designed for a panel of known mutations (Supplementary Table 1 ). After PCR and single nucleotide extension reactions were performed, the resulting extension products were analyzed using a matrix-assisted laser desorption/ ionization-time-of-flight (MALDI-TOF) mass spectrometer, as previously reported.(11)
Sanger Sequencing
Bidirectional Sanger sequencing of mutations detected by Sequenom was performed as previously reported. (11, 12) Primer sequences are available upon request.
Statistics
This analysis was designed as an exploratory study to quantify the frequency of BRAF mutations in patients with advanced GCT who required treatment with cisplatin. Since 
RESULTS
Patient Characteristics
Of 75 patients, 73 had nonseminoma and two had seminoma. The median age at diagnosis was 30 (range 14 to 60 years). Primary site was testis in 62 and mediastinum in 13. Twenty-five patients had cisplatin-sensitive tumors and 50 had cisplatin-resistant tumors. Additional patient characteristics divided by cisplatin sensitivity status are provided in Table 1 . 
Tumor Sample Characteristics
In five cases, DNA quality was inadequate for evaluation, resulting in 70 samples suitable for mutation analysis, 43 of which were primary tumors (34 testicular and nine mediastinal) and 27 of which were metastatic samples, (predominantly retroperitoneal lymph nodes). . Of 27 metastatic samples, the primary tumor was testis in 23 and mediastinum in four.
Sixty-eight tumors were nonseminoma and two were seminoma. Of the 68 nonseminomas, histology was mixed in 32 cases, a solitary histology in 34 cases, and two cases were nonseminoma, NOS. Teratoma with secondary somatic malignant differentiation was present in five samples with the transformed malignancy consisting of sarcoma in three and primitive neuroepithelial tumor (PNET) in two cases.
Twenty-seven tumors were obtained before chemotherapy and 43 after ≥1 line of prior chemotherapy. Fourteen of 43 tumors obtained post-chemotherapy were pure teratoma (n=12) or a combination of teratoma plus teratoma with malignant transformation (n=2) without other viable GCT elements. Sample characteristics divided by cisplatinresponsiveness are listed in Table 2 .
Mutations and Association with Cisplatin Resistance
Nineteen mutations were found in 16 (23%) of the 70 tumors evaluated, including one tumor with three mutations and a second with two mutations (Tables 3 and 4 (Table 3) In contrast to FGFR3, all other mutations were identified only within cisplatin-resistant tumors (Table 3 ). All three AKT1 mutations were E17K, whereas there was heterogeneity among KRAS (G12D, G12C, G13D) and PIK3CA mutations (one E542K, two E545K). The lone HRAS mutation was G12S.
Overall, mutations were found in 13% of cisplatin-sensitive tumors (all FGFR3) and 28% of cisplatin-resistant tumors. Coexisting mutations included FGFR3 and AKT1 in one patient and FGFR3, AKT1, and HRAS in another patient. (Table 4 )
Correlation of Mutation Status with Clinicopathologic Factors
There was no apparent association between mutation frequency and whether the sample was taken from the primary tumor or metastatic lesion (26% vs. 19%, Table 5 ).
A higher proportion of mutations was observed among mediastinal as compared to testicular primary tumors (31% vs. 21%) but this did not reach statistical significance ( 
NSGCT), a subset analysis excluding patients with PM-NSGCT did not significantly affect the frequency of any mutation. Interestingly, both patients with multiple mutations in the same tumor had PM-NSGCT and their tumors contained FGFR3 and AKT1 mutations. All patients with solitary FGFR3 mutations had tumors of testicular origin. (Table 4) Mutations were observed across all histologies, including 14 of 68 patients with nonseminoma and both patients with pure seminoma (Table 5) 
mutations other than FGFR3 (PIK3CA, AKT1, KRAS, and HRAS) were associated with cisplatin-resistance (p=0.023) and the presence of yolk sac tumor without teratoma (p=0.018). A trend towards more frequent non-FGFR3 mutations was also observed for mediastinal primary tumors (p=0.055). (Supplementary Table 2) None of the nine GCT cell lines contained mutations in BRAF or the other genes assessed.
DISCUSSION
In this study, mutations in several well-known oncogenes, including FGFR3, PIK3CA, AKT1, KRAS, and HRAS, but not BRAF or NRAS, were identified in tumors from patients with advanced GCT. Historically, mutations in well-characterized oncogenes and tumor suppressors have been thought to be extremely uncommon events in GCT. BRAF mutations within 9 (26%) of 35 cisplatin-resistant GCT compared to 1 (1%) of 100 randomly selected GCT (cisplatin-resistance unknown).(6) The authors hypothesized that BRAF mutations occur frequently in relapsed or refractory GCT and may play a role in the development of cisplatin resistance. Of note, cisplatin resistance in GCT is defined differently than in other solid tumor malignancies. Due to its high cure rate, anything short of cure (incomplete response or relapse), no matter how significant the initial response, is considered indicative of cisplatin resistance.
We sought to confirm this finding in a larger cohort of cisplatin-resistant GCT. However, none of the 70 tumors (including 46 cisplatin-resistant) or 9 GCT cell lines tested harbored a BRAF mutation. The discrepancy between our results and Honecker's findings could relate to differences in mutational analysis techniques, differences in definition of cisplatin-resistance, or ethnic differences within the patient populations screened (German vs. American), as observed in other malignancies such as prostate cancer. (14) However, it is notable that our findings are consistent with the other three series that evaluated GCT for BRAF mutations (Table 7 ).(7-9) Two of these failed to identify any BRAF mutations and the remaining study reported a rate of only 5% among 62 samples. In addition, two of these studies were conducted in Germany, (7, 8) Of the seven genes evaluated, FGFR3 was the most frequently mutated despite no prior reports of FGFR3 mutations in GCT (although other FGFR3 alterations have been reported). As observed in other malignancies such as bladder cancer (15), the presence of an FGFR3 mutation in GCT was not associated with cisplatin-sensitivity or resistance (identified in 13% of samples in both groups). In addition, to our knowledge, we report for the first time AKT1 and PIK3CA activating mutations in patients with GCT.
Importantly, all mutations in PIK3CA and AKT1 were present only within cisplatinresistant tumors and mutations in these two genes were mutually exclusive as expected for genes whose protein products are found within the same oncogenic pathway. 
trials of PI3K/AKT-selective inhibitors in combination with chemotherapy in patients with poor-risk previously untreated GCT and those with established cisplatin resistance. The data also suggest a need to develop novel cell lines more representative of the genetic profile of cisplatin-resistant GCT to serve as in vitro models for testing novel targeted therapies.
In addition to cisplatin-resistance, mutations other than FGFR3 were associated with tumors that contained yolk sac elements but lacked teratoma (although observed across all histologies). Importantly, our analysis confirmed that these mutations represent events occurring within GCT components rather than being acquired during somatic malignant differentiation of teratoma. Only two of 16 tumors with mutations had a secondary somatic malignant component and in both cases, a block lacking the secondary somatic cancer was used for sequencing. There was also a strong trend toward a higher rate of non-FGFR3 mutations among patients with mediastinal as compared to testicular primary tumors. Even among poor-risk GCT, primary mediastinal nonseminomas tend to have higher rates of cisplatin-resistance and more unfavorable outcomes. A higher predilection toward acquiring mutations could partially explain their more aggressive phenotype.
In contrast, there was no difference in mutational frequency among post-chemotherapy (vs. pre-chemotherapy) samples, suggesting mutation acquisition was not a consequence of chemotherapy exposure. However, such a conclusion is limited by the small number of samples studied and lack of paired primary/metastatic and pre-/post- We also performed an exploratory analysis (Supplemental Figure 2) to evaluate the association between mutation status and survival. Although a trend toward worse survival was observed for patients whose tumors harbored mutations, given our cohort was enriched for cisplatin-resistant tumors and mutations were more common among cisplatin-resistant samples, this analysis was inherently biased. This was easily demonstrated by confining the analysis to only cisplatin-resistant tumors which resulted in no differences in survival between patients with and without mutations (Supplemental Figure 3) . In summary, we were unable to validate the finding of frequent BRAF mutations in American patients with cisplatin-resistant GCT, despite evaluation of the largest cohort of cisplatin-resistant cases studied to date. However, we found mutations in other oncogenes in 28% of cisplatin-resistant GCT, including for the first time, FGFR3, AKT1, and PIK3CA. While FGFR3 mutations were identified within both sensitive and resistant tumors, all other mutations were exclusive to platinum-resistant tumors. A more detailed genetic analysis of cisplatin-resistant GCT for these and other mutations using Next Generation sequencing technologies will hopefully define their prevalence in this disease. Evaluation of paired primary/metastatic and pre-/post-chemotherapy samples will also aid in determining whether a certain proportion of GCT contain an intrinsically cisplatin-resistant clone prior to chemotherapy or whether resistance is more commonly the result of tumor acquisition of new mutations on treatment. Ultimately, such findings could lead to the identification of novel drug targets for the treatment of patients with recurrent, cisplatin-resistant disease and the development of combinatorial therapies that prevent or delay the emergence of drug-resistant clones. Abbreviations: IGCCCG, International Germ Cell Tumor Collaborative Group; RP, retroperitoneum; T, teratoma unspecified; YS, yolk sac tumor; T(M), mature teratoma; EC, embryonal carcinoma; RMS, rhabdomyosarcoma; T(I), immature teratoma; CC, choriocarcinoma; NSGCT, nonseminomatous germ cell tumor; NOS, not otherwise specified; PNET, primitive neuroepithelial tumor *Patient presented with large mediastinal primary tumor and 3 years later relapsed in adrenal gland and retroperitoneum **Although RMS was present in this patient's tumor, the block selected for DNA extraction contained no RMS and was a mixture of T (M) and EC ***Although PNET was present in this patient's tumor, the block selected for DNA extraction contained no PNET and was purely EC. 
